Cytori Therapeutics (CYTX) Reaches New 52-Week Low at $0.24
Cytori Therapeutics Inc (NASDAQ:CYTX) reached a new 52-week low on Thursday . The company traded as low as $0.24 and last traded at $0.24, with a volume of 515000 shares. The stock had previously closed at $0.25.
A number of research firms recently weighed in on CYTX. Maxim Group set a $5.00 price target on shares of Cytori Therapeutics and gave the stock a “buy” rating in a research note on Thursday, October 19th. Zacks Investment Research downgraded shares of Cytori Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, November 9th. Finally, B. Riley reissued a “hold” rating on shares of Cytori Therapeutics in a research note on Tuesday, November 7th.
Cytori Therapeutics (NASDAQ:CYTX) last issued its earnings results on Thursday, November 9th. The biotechnology company reported ($0.14) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.16) by $0.02. Cytori Therapeutics had a negative net margin of 367.33% and a negative return on equity of 228.21%. The firm had revenue of $1.77 million during the quarter, compared to the consensus estimate of $2.04 million. During the same quarter in the prior year, the firm earned ($0.26) earnings per share. equities research analysts predict that Cytori Therapeutics Inc will post -0.62 earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: This article was posted by Watch List News and is the property of of Watch List News. If you are reading this article on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The original version of this article can be viewed at https://www.watchlistnews.com/cytori-therapeutics-cytx-reaches-new-52-week-low-at-0-24/1767475.html.
Cytori Therapeutics Company Profile
Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.
Receive News & Ratings for Cytori Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.